1.90 (-%)
As of Nov 11, 2024
Source:
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | 617-500-8099 |
| Industry | manufacturing |
| CEO | Thomas J. Schuetz |
| Website | www.clinicaltrials.gov |